nalysis of factors related to the absorption rate of papillary thyroid microcarcinoma after ultrasound-guided radiofrequency ablation

doi:10.3969/j.issn.1006-7795.2023.06.006

Abstract

Abstract: Objective To explore the ultrasound and pathological factors related to the absorption rate of ultrasound-guided radiofrequency ablation(RFA) in the treatment of papillary thyroid microcarcinoma (PTMC).Methods This study performed a retrospective analysis of patients with ultrasound-guided RFA for PTMC between December 2020 and March 2022. General information of patients was collected before RFA, and follow-up was performed at 1, 3, 6, 12 and 18 months after RFA to obtain changes in thyroid nodules volume. Taking the time when postoperative nodules reach 100% volume reduction ratio (VRR) as the absorption rate evaluation index, univariate χ2 test and Logistic regression were used to analyze the influencing factors of RFA treatment.Results A total of 64 TNs in 56 patients reached 100% VRR 18 months after RFA, the mean VRR of nodules at 1, 3, 6, 12, and 18 months after RFA were 61.43%, 87.86%, 96.62%, 99.70% and 100%.Through the analysis of ultrasound features, it was found that the nodule volume greater than 0.08 mL and the RFA time longer than 130 s were associated with low absorption rate (100% VRR time greater than 12 months). PTMC patients with Bethesda grade Ⅲ have a lower rate of absorption than patients with Bethesda class Ⅴ/Ⅵ. In addition, PTMC patients with Hashimoto's thyroiditis are associated with low absorption rate. Logistic regression analysis showed that RFA was independent influencing factors affecting the rate of absorption after RFA in PTMC patients. Conclusion Ultrasound features affecting the absorption rate of TNs by ultrasound-guided RFA include nodules volume,duration of RFA, Bethesda grade and Hashimoto's thyroiditis. RFA was independent factors of PTMC absorption rate after RFA.

Key words: ultrasound-guided radiofrequency ablation, papillary thyroid microcarcinoma, Bethesda grade, Hashimoto's thyroiditis

CLC Number:

R445

Jia Xiaoxia, Chang Ying, Hou Wenying, Fu Ying, Zhang Huidan, Yang Jingchun. nalysis of factors related to the absorption rate of papillary thyroid microcarcinoma after ultrasound-guided radiofrequency ablation[J]. Journal of Capital Medical University, 2023, 44(6): 941-947.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.06.006

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I6/941

References

［1］Tuttle R M, Li D, Ridouani F. Percutaneous ablation of low-risk papillary thyroid cancer［J］. Endocr Relat Cancer, 2023, 30(3): e220244.
［2］Haugen B R, Alexander E K, Bible K C, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer［J］. Thyroid, 2016, 26(1): 1－133.
［3］Tuttle R M, Alzahrani A S. Risk stratification in differentiated thyroid cancer: from detection to final follow-up［J］. J Clin Endocrinol Metab, 2019, 104(9): 4087－4100.
［4］Chou R, Dana T, Haymart M, et al. Active surveillance versus thyroid surgery for differentiated thyroid cancer: a systematic review［J］. Thyroid, 2022, 32(4): 351－367.
［5］Hegedüs L, Miyauchi A, Tuttle R M. Nonsurgical thermal ablation of thyroid nodules: not if, but why, when, and how?［J］. Thyroid, 2020, 30(12):1691－1694.
［6］Min Y, Wang X, Chen H, et al. Thermal ablation for papillary thyroid microcarcinoma: how far we have come?［J］. Cancer Manag Res, 2020, 12:13369－13379.
［7］Tufano R P, Pace-Asciak P, Russell J O, et al. Update of radiofrequency ablation for treating benign and malignant thyroid nodules. the future is now［J］. Front Endocrinol (Lausanne), 2021, 12: 698689.
［8］Baldwin C K, Natter M B, Patel K N, et al. Minimally invasive techniques for the management of thyroid nodules［J］. Endocrinol Metab Clin North Am, 2022, 51(2): 323－349.
［9］Pace-Asciak P, Russell J O, Tufano R P. The treatment of thyroid cancer with radiofrequency ablation［J］. Tech Vasc Interv Radiol, 2022, 25(2): 100825.
［10］Chung S R, Suh C H, Baek J H, et al. Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: a systematic review and meta-analysis［J］. Int J Hyperthermia, 2017, 33(8): 920－930.
［11］Muhammad H, Santhanam P, Russell J O. Radiofrequency ablation and thyroid nodules: updated systematic review［J］. Endocrine, 2021, 72(3): 619－632.
［12］Lim J Y, Kuo J H. Thyroid nodule radiofrequency ablation: complications and clinical follow up［J］. Tech Vasc Interv Radiol, 2022, 25(2): 100824.
［13］Yang Z, Yan L, Xiao J, et al. Long-term results of radiofrequency ablation for locally recurrent papillary thyroid carcinoma［J］. Int J Hyperthermia, 2023, 40(1): 2191912.
［14］Pak S J, Lee Y M, Kim P N, et al. Short-term outcome of adrenal radiofrequency ablation of adrenal cysts: a single-center experience［J］. Sci Rep, 2023, 13(1): 3267.
［15］Nguyen V B, Nguyen Thi X, Nguyen Van Vy H, et al. Radiofrequency versus ethanol ablation for single-session treatment of benign cystic thyroid nodules: a short-term retrospective study［J］. Ther Clin Risk Manag, 2023, 19: 97－104.
［16］Zhang C, Yin J, Hu C L, et al. Comparison of ultrasound guided percutaneous radiofrequency ablation and open thyroidectomy in the treatment of low-risk papillary thyroid microcarcinoma: a propensity score matching study［J］. Clin Hemorheol Microcirc, 2022, 80(2): 73－81.
［17］Kim J H, Baek J H, Lim H K, et al. 2017 thyroid radiofrequency ablation guideline: Korean society of thyroid radiology［J］. Korean J Radiol, 2018, 19(4): 632－655.
［18］Papini E, Monpeyssen H, Frasoldati A, et al. 2020 European thyroid association clinical practice guideline for the use of image-guided ablation in benign thyroid nodules［J］. Eur Thyroid J, 2020, 9(4): 172－185.
［19］Ha E J, Baek J H, Che Y, et al. Radiofrequency ablation of benign thyroid nodules: recommendations from the Asian conference on tumor ablation task force-secondary publication［J］. J Med Ultrasound, 2021, 29(2): 77－83.
［20］Mauri G, Hegedüs L, Bandula S, et al. European thyroid association and cardiovascular and interventional radiological society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions［J］. Eur Thyroid J, 2021, 10(3): 185－197.
［21］Wu L F, Zhou Y Y, Guan Y Y, et al. Washout DNA copy number analysis by low-coverage whole genome sequencing for assessment of thyroid FNAs［J］. Front Endocrinol (Lausanne), 2022, 13: 888072.
［22］Du J, Han R J, Chen C, et al. Diagnostic efficacy of ultrasound, cytology, and BRAFV600E mutation analysis and their combined use in thyroid nodule screening for papillary thyroid microcarcinoma［J］. Front Oncol, 2021, 11: 746776.
［23］Rosario P W, Mourão G F, Calsolari M R. Active surveillance in adults with low-risk papillary thyroid microcarcinomas: a prospective study［J］. Horm Metab Res, 2019, 51(11): 703－708.
［24］Gao Y, Qu N, Zhang L, et al. Preoperative ultrasonography and serum thyroid-stimulating hormone on predicting central lymph node metastasis in thyroid nodules as or suspicious for papillary thyroid microcarcinoma［J］. Tumour Biol, 2016, 37(6): 7453－7459.
［25］Zha X J, Miao Z C, Huang X, et al. The risk stratification of papillary thyroid cancer with Bethesda category Ⅲ (atypia of undetermined significance/follicular lesion of undetermined significance) by thyroid fine-needle aspiration could be assisted by tumor size for precision treatment［J］. Front Endocrinol (Lausanne), 2022, 13: 822423.
［26］Dobrinja C, Bernardi S, Fabris B, et al. Surgical and pathological changes after radiofrequency ablation of thyroid nodules［J］. Int J Endocrinol, 2015, 2015: 576576.
［27］Issa P P, Omar M, Issa C P, et al. Radiofrequency ablation of indeterminate thyroid nodules: the first North American comparative analysis［J］. Int J Mol Sci, 2022, 23(19): 11493.
［28］Caturegli P, De Remigis A, Rose N R. Hashimoto thyroiditis: clinical and diagnostic criteria［J］. Autoimmun Rev, 2014, 13(4/5): 391－397.
［29］Ieni A, Vita R, Magliolo E, et al. One-third of an Archivial series of papillary thyroid cancer (years 2007-2015) has coexistent chronic lymphocytic thyroiditis, which is associated with a more favorable tumor-node-metastasis staging［J］. Front Endocrinol (Lausanne), 2017, 8: 337.
［30］Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, et al. Association between Hashimoto's thyroiditis and thyroid cancer in 64,628 patients［J］. Front Oncol, 2017, 7: 53.
［31］Ralli M, Angeletti D, Fiore M, et al. Hashimoto's thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation［J］. Autoimmun Rev, 2020, 19(10): 102649.
［32］Zheng H T, Xu J, Chu Y L, et al. A global regulatory network for dysregulated gene expression and abnormal metabolic signaling in immune cells in the microenvironment of graves' disease and Hashimoto's thyroiditis［J］. Front Immunol, 2022, 13: 879824.
［33］Zhang Y, Zhang M B, Luo Y K, et al. Effect of chronic lymphocytic thyroiditis on the efficacy and safety of ultrasound-guided radiofrequency ablation for papillary thyroid microcarcinoma［J］. Cancer Med, 2019, 8(12): 5450－5458.
［34］Yan L, Liu Y, Li W H, et al. Long-term outcomes of ultrasound-guided thermal ablation for the treatment of solitary low-risk papillary thyroid microcarcinoma: a multicenter retrospective study［J］. Ann Surg, 2023, 277(5): 846－853.
［35］Lai L M, Liu Z H, Zhang J W, et al. Effect of Hashimoto's thyroiditis on the extent of the ablation zone in early stages of ultrasound-guided radiofrequency ablation for papillary thyroid microcarcinoma: a large cohort study of 772 patients［J］. Int J Hyperthermia, 2022, 39(1): 397－404.

[1]	Song Haiman, He Wen, Kang Ruijun, Wang Lishu, Yu Tengfei, Zhang Wei. Application of ovarian-adnexal ultrasound reporting and data system in the diagnosis of ovarian benign and malignant tumors [J]. Journal of Capital Medical University, 2023, 44(6): 948-952.
[2]	Yu Tengfei, Yin Lu, Tian Daoran, Song Haiman, Yin Ziyi, Zhang Wei, He Wen . The value of combined superb microvascular imaging and color Doppler flow imaging in breast BI-RADS class 4 micronodules [J]. Journal of Capital Medical University, 2023, 44(6): 921-927.
[3]	Wei Xingyue, Wang Lianshuang, Wang Yuanyuan, Gao Mengze, He Qiong, Zhang Yao, Luo Jianwen. Intelligent grading diagnosis of liver fibrosis, inflammation, and steatosis in chronic liver disease based on multimodal ultrasound imaging data [J]. Journal of Capital Medical University, 2023, 44(6): 928-935.
[4]	Zhuang Jiamian, Zeng Yuran, Chen Shaoqi. Evaluation of the mechanical properties of supraspinatus tendons in hemodialysis patients with high frame rate sound touch elastography [J]. Journal of Capital Medical University, 2023, 44(6): 936-940.
[5]	Song Qian, Zhou Qian, Sun Hong, Li Shuo, Mei Xue, Guo Ruijun, Ge Huiyu. Clinical value of Lindegaard in the early diagnosis of sepsis-associated encephalopathy [J]. Journal of Capital Medical University, 2023, 44(6): 959-965.
[6]	Sun Zhe, Ma Jiaojiao, Zhang Bo. Application status and prospects of pleural ultrasound in respiratory diseases [J]. Journal of Capital Medical University, 2023, 44(6): 966-972.
[7]	Song Haiman, He Wen, Kang Ruijun, Wang Lishu, Yu Tengfei, Zhang Wei. Application of ovarian-adnexal ultrasound reporting and data system in the diagnosis of ovarian benign and malignant tumors [J]. Journal of Capital Medical University, 0, (): 948-952.
[8]	Zhang Shu, Wang Kai, Yang Zihao, Qiao Zhen, Li Xiaotong, Yuan Leilei, Ai Lin. Application of ¹¹C-MET PET/CT in screening isocitric dehydrogenase and 1p/19q status in supratentorial lower-grade gliomas [J]. Journal of Capital Medical University, 2022, 43(6): 826-833.
[9]	Geng Yiqiang, Liu Jiajin, Wu Shina, Sun Shuwei, Zhao Dong, Song Jingbin, Sun Yabing, Wang Ruimin. Evaluation of the effect of NEMA NU 2-2018 Standards in performance test of PET/CT system [J]. Journal of Capital Medical University, 2022, 43(6): 840-844.
[10]	Xu Yang, Wang Kai, Chen Qiang, Ai Lin. Advances about molecular imaging of nuclear medicine in diagnosis and treatment of glioma [J]. Journal of Capital Medical University, 2022, 43(6): 880-885.
[11]	Huang Lixiang, Wang Shaozhou, Cao Chen, Xia Shuang. To explore the influence of lenticulostriate artery on quantitative perfusion of basal ganglia brain tissue and predict the prognosis of patients [J]. Journal of Capital Medical University, 2022, 43(1): 53-60.
[12]	Wang Li, Shi Zhao, Kong Xiang, Yang Liu, Liu Ya, Luo Song, Zhang Longjiang. Association between A1 segment dysplasia, bifurcation angles of anterior cerebral artery and the formation of anterior communicating aneurysms [J]. Journal of Capital Medical University, 2022, 43(1): 61-66.
[13]	Zhang Huibo, Yang Xiaoxu, Liu Xinyuan, Gu Hua, Wang Shuangkun, Yang Qi. Diagnostic value of magnetic resonance imaging for cerebral venous sinus thrombosis [J]. Journal of Capital Medical University, 2022, 43(1): 67-73.
[14]	Sun Penghui, Li Yingying, Liu Xin, Jia Xuejia, Jia Xiuqin, Yang Qi. Prediction on neurological deterioration based on imaging features in patients with stroke-associated pneumonia [J]. Journal of Capital Medical University, 2022, 43(1): 74-81.
[15]	Kang Li, Li Shuo, Xiong Ying, Guo Ruijun. Clinical value of torasemide combined with 50% glucose rapid diuretic ultrasonography in the diagnosis of renal microcalculi in pilot service [J]. Journal of Capital Medical University, 2021, 42(6): 1076-1080.